ATM regulates target switching to escalating doses of radiation in the intestines

Author:  ["Hui-Ju Ch'ang","Jerzy G Maj","François Paris","H Rosie Xing","Jianjun Zhang","Jean-Philip Truman","Carlos Cardon-Cardo","Adriana Haimovitz-Friedman","Richard Kolesnick","Zvi Fuks"]

Publication:  Nature Medicine

CITE.CC academic search helps you expand the influence of your papers.

Tags:     Medicine

Abstract

Although stem cells succumbing to reproductive death are assumed to be the single relevant targets in radiation tissue damage, recent studies showed intestinal stem cell damage is conditionally linked to crypt endothelial apoptosis, defining a two-target model. Here we report that when mouse intestines were protected against microvascular apoptosis, radiation switched as the dose escalated to a previously unrecognized crypt stem cell target, activating ceramide synthase–mediated apoptosis to initiate intestinal damage. Whereas ataxia telangiectasia-mutated (ATM) kinase normally represses ceramide synthase, its derepression in Atm−/− mice increased crypt stem cell radiosensitivity 3.7-fold without sensitizing the microvascular response. Discovery of this intestinal radiosensitivity mechanism allowed design of an antisense Atm oligonucleotide treatment which phenocopied the Atm−/− mouse, reordering ceramide synthase–mediated stem cell death to become the first-line gastrointestinal response of wild-type littermates. These experiments indicate that tissues operate multiple potential targets activated consecutively according to their inherent radiosensitivities that may be reordered therapeutically to control radiation tissue responses.

Cite this article

Ch'ang, HJ., Maj, J., Paris, F. et al. ATM regulates target switching to escalating doses of radiation in the intestines. Nat Med 11, 484–490 (2005). https://doi.org/10.1038/nm1237

View full text

>> Full Text:   ATM regulates target switching to escalating doses of radiation in the intestines

Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in tra

A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease